tiprankstipranks
Advertisement
Advertisement

HK:2616 Stock Latest News

CStone’s New EGFR–HER3 Drug CS5007 Enters First-in-Human Testing: What Investors Should Know
Company AnnouncementsCStone’s New EGFR–HER3 Drug CS5007 Enters First-in-Human Testing: What Investors Should Know
2d ago
2616
CStone Seeks Independent Shareholder Approval for CEO Equity Awards
PremiumCompany Announcements
CStone Seeks Independent Shareholder Approval for CEO Equity Awards
4d ago
2616
CStone Launches Global Phase I Trial for New EGFR/HER3 Bispecific ADC
PremiumCompany Announcements
CStone Launches Global Phase I Trial for New EGFR/HER3 Bispecific ADC
9d ago
2616
CStone Executives Launch Joint Share Purchase Plan to Signal Confidence in Pipeline
PremiumCompany Announcements
CStone Executives Launch Joint Share Purchase Plan to Signal Confidence in Pipeline
17d ago
2616
CStone Sets 2026 AGM to Renew Board, Auditor and Share Issuance Mandate
PremiumCompany Announcements
CStone Sets 2026 AGM to Renew Board, Auditor and Share Issuance Mandate
19d ago
2616
CStone’s CS2009 Posts Strong ASCO Data as Company Prepares Global Phase III Trial
PremiumCompany AnnouncementsCStone’s CS2009 Posts Strong ASCO Data as Company Prepares Global Phase III Trial
20d ago
2616
CStone Pharmaceuticals Unveils Share Buyback Plan After Key Oncology Data Milestone
Premium
Company Announcements
CStone Pharmaceuticals Unveils Share Buyback Plan After Key Oncology Data Milestone
1M ago
2616
CStone Launches Nationwide Supply of Locally Made Pralsetinib as China Sales Surge
Premium
Company Announcements
CStone Launches Nationwide Supply of Locally Made Pralsetinib as China Sales Surge
1M ago
2616
CStone Pharmaceuticals Raises Over HK$1 Billion in Completed Share Placement
PremiumCompany Announcements
CStone Pharmaceuticals Raises Over HK$1 Billion in Completed Share Placement
2M ago
2616
CStone to Showcase Promising CS2009 Cancer Data Ahead of Global Phase III Push
PremiumCompany Announcements
CStone to Showcase Promising CS2009 Cancer Data Ahead of Global Phase III Push
2M ago
2616
CStone Showcases Three Novel ADC Candidates, Highlighting EGFR/HER3 Bispecific CS5007
PremiumCompany Announcements
CStone Showcases Three Novel ADC Candidates, Highlighting EGFR/HER3 Bispecific CS5007
2M ago
2616
CStone Pharmaceuticals to Raise About HK$1.05 Billion via Discounted Share Placement
PremiumCompany Announcements
CStone Pharmaceuticals to Raise About HK$1.05 Billion via Discounted Share Placement
2M ago
2616
CStone’s 2025 Loss Widens as R&D Spend Climbs Ahead of Pralsetinib NRDL Boost
PremiumCompany AnnouncementsCStone’s 2025 Loss Widens as R&D Spend Climbs Ahead of Pralsetinib NRDL Boost
3M ago
2616
CStone Fast-Tracks Global Phase III Plan After Strong Early Data for Trispecific Cancer Antibody CS2009
Premium
Company Announcements
CStone Fast-Tracks Global Phase III Plan After Strong Early Data for Trispecific Cancer Antibody CS2009
3M ago
2616
CStone’s Sugemalimab Wins Top ESMO Backing for Stage III Lung Cancer
Premium
Company Announcements
CStone’s Sugemalimab Wins Top ESMO Backing for Stage III Lung Cancer
3M ago
2616
CStone to Showcase Three ADC Pipeline Programs at 2026 AACR Meeting
PremiumCompany Announcements
CStone to Showcase Three ADC Pipeline Programs at 2026 AACR Meeting
3M ago
2616
CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab
PremiumCompany Announcements
CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab
4M ago
2616
CStone Wins U.S. FDA Green Light for Phase II Trial of Trispecific Cancer Antibody CS2009
PremiumCompany Announcements
CStone Wins U.S. FDA Green Light for Phase II Trial of Trispecific Cancer Antibody CS2009
4M ago
2616
CStone Pharmaceuticals Streamlines Company Secretary and Authorized Representative Roles
PremiumCompany Announcements
CStone Pharmaceuticals Streamlines Company Secretary and Authorized Representative Roles
4M ago
2616
CStone Pharmaceuticals Sets March Board Meeting and Investor Call to Detail 2025 Results and Oncology Pipeline Progress
PremiumCompany AnnouncementsCStone Pharmaceuticals Sets March Board Meeting and Investor Call to Detail 2025 Results and Oncology Pipeline Progress
5M ago
2616
CStone CEO Boosts Stake to 4.87% in Sign of Long-Term Confidence
Premium
Company Announcements
CStone CEO Boosts Stake to 4.87% in Sign of Long-Term Confidence
5M ago
2616
CStone Pharmaceuticals Grants New Share Options and RSUs, Seeks Shareholder Nod for Director Awards
Premium
Company Announcements
CStone Pharmaceuticals Grants New Share Options and RSUs, Seeks Shareholder Nod for Director Awards
5M ago
2616

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >